Amgen Pulls Out of AstraZeneca Psoriasis Drug Deal

Because of results from late stage clinical development, Amgen terminated an agreement with AstraZeneca on an experimental psoriasis drug. Patients reported suicidal thoughts during clinical testing, according to an article in the Philadelphia Business Journal.

Amgen said the likelihood of the drug being required to carry warning labels of suicide risk would limit the potential market for the treatment. AstraZeneca said the company will review study data and will make an announcement regarding the drug brodalumab as soon as possible. Read the full story